Cannabimimetic fatty acid derivatives in cancer and inflammation

Prostaglandins and Other Lipid Mediators

Volumn 61, Issue 1-2, 2000, Pages 43-61

  Di Marzo, Vincenzo ^a   Melck, Dominique ^a   De Petrocellis, Luciano ^b   Bisogno, Tiziana ^a  

^a Istituto per la Chimica di Molecole di Interesse Biologico   (Italy)

^b CNR   (Italy)

Author keywords

2 Arachidonoyl glycerol; Anandamide; Cancer; Cannabinoid; Inflammation; Pain; Palmitoylethanolamide; Receptor; Tumor cell proliferation

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ANTIGEN; CALCIUM IONOPHORE; CANNABINOID; CANNABINOID RECEPTOR; FATTY ACID DERIVATIVE; IONOMYCIN; LIPOPOLYSACCHARIDE; NERVE GROWTH FACTOR RECEPTOR; PALMIDROL; PROLACTIN RECEPTOR; RECEPTOR SUBTYPE; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

BIOSYNTHESIS; BREAST CANCER; CANCER; CELL ACTIVATION; CELL PROLIFERATION; HUMAN; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MAST CELL LEUKEMIA; NONHUMAN; PROSTATE CANCER; REVIEW; TUMOR CELL LINE;

EID: 0034001560     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(00)00054-X     Document Type: Article

References (99)

1. Mechoulam R. The pharmacohistory of Cannabis sativa. Mechoulam R. Cannabinoids as therapeutic agents. 1986;1-19 CRS Press, Boca Raton, FL.
2. Martin B.R. Cellular effects of cannabinoids. Pharmacol Rev. 38:1986;45-74.
3. Grotenhermen F. Therapeutic use of cannabis. Lancet. 351:1998;758-759.
4. Burstein S. Marijuana as a medicine. Nature. 386:1997;320.
5. Devane WA, Hanu L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-9.
6. Mechoulam R, Ben-Shabat S, Hanu L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90.
7. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol a possible endogenous cannabinoid receptor ligand in brain . Biochem Biophys Res Commun. 215:1995;89-97.
8. Di Marzo V. 'Endocannabinoids', and other fatty acid derivatives with cannabimimetic properties biochemistry and possible physiopathological relevance . Biochim Biophys Acta. 1392:1998;153-175.
9. Skaper S.D., Buriani A., Dal Toso R., Petrelli L., Romanello S., Facci L., et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA. 93:1996;3984-3989.
10. Molina-Holgado F., Molina-Holgado E., Guaza C. The endogenous cannabinoid anandamide potentiates IL-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett. 433:1998;139-142.
11. Di Marzo V., Melck D., Bisogno T., De Petrocellis L. Endocannabinoids, endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21:1998;521-528.
12. Martin B.R., Lichtman A.H. Cannabinoid transmission and pain perception. Neurobiol Dis. 5:1998;447-461.
13. Kaminski N.E. Inhibition of the cAMP signaling cascade via cannabinoid receptors a putative mechanism of immune modulation by cannabinoid compounds . Toxicol Lett. 102:1998;59-63.
14. Randall M.D., Kendall D.A. Endocannabinoids a new class of vasoactive substances. Trends Pharmacol Sci. 19:1998;55-58.
15. Wagner J.A., Varga K., Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med. 76:1998;824-836.
16. Murphy L.L., Munoz R., Adrian B.A., Villanua M.A. Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis. 5:1998;432-446.
17. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis. 5:1998;534-551.
18. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., et al. SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
19. 2 cannabinoid receptor. J Pharmacol Exp Ther. 284:1998;644-650.
20. Ouyang Y., Hwang S.G., Han S.H., Kaminski N.E. Suppression of IL-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. Mol Pharmacol. 53:1998;676-683.
21. Burstein S.H. The cannabinoid acids nonpsychoactive derivatives with therapeutic potential . Pharmacol Ther. 82:1999;87-96.
22. Holdcroft A., Smith M., Jacklin A., Hodgson H., Smith B., Newton M., et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia. 52:1997;483-486.
23. Bisogno T., Maurelli S., Melck D., De Petrocellis L., Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem. 272:1997;3315-3323.
24. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87.
25. Di Marzo V., Bisogno T., Melck D., Ross R., Brockie H., Stevenson L., et al. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. 436:1998;449-454.
26. Di Marzo V., Bisogno T., Sugiura T., Melck D., De Petrocellis L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells connections with anandamide . Biochem J. 331:1998;15-19.
27. Di Marzo V., De Petrocellis L., Sepe N., Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J. 316:1996;977-984.
28. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J.A., et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem. 264:1999;258-267.
29. Pestonjamasp V.K., Burstein S.H. Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochim Biophys Acta. 1394:1998;249-260.
30. 1 cannabinoid receptors in haemorrhagic shock. Nature. 390:1997;518-521.
31. Varga K., Wagner J.A., Bridgen D.T., Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12:1998;1035-1044.
32. Maccarrone M., van der Stelt M., Rossi A., Veldink G.A., Vliegenthart J.F., Finazzi-Agro' A. Anandamide hydrolysis by human cells in culture and brain. J Biol Chem. 273:1998;32332-32339.
33. Maccarrone M., Bari M., Menichelli A., Del Principe D., Finazzi-Agro' A. Anandamide activates human platelets through a pathway independent of the arachidonate cascade. FEBS Lett. 447:1999;277-282.
34. Edgemond W.S., Hillard C.J., Falck J.R., Kearn C.S., Campbell W.B. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide) their affinities for cannabinoid receptors and pathways of inactivation . Mol Pharmacol. 54:1998;180-188.
35. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA. 92:1995;3376-3380.
36. Lambert D.M., Di Marzo V. The palmitoylethanolamide and oleamide Enigmas are these two fatty acid amides cannabimimetic? Curr Med Chem. 6:1999;757-773.
37. Burstein S.H., Young J.K., Wright G.E. Relationships between eicosanoids and cannabinoids. Are eicosanoids cannabimimetic agents? Biochem Pharmacol. 50:1995;1735-1742.
38. Di Marzo V., De Petrocellis L., Bisogno T., Maurelli S. The endogenous cannabimimetic eicosanoid, anandamide, induces arachidonate release in J774 mouse macrophages. Adv Exp Med Biol. 407:1997;341-346.
39. Hunter S.A., Burstein S.H. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Life Sci. 60:1997;1563-1573.
40. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA. 90:1993;7656-7660.
41. 2 receptors. Mol Pharmacol. 48:1995;443-450.
42. Berdyshev E.V., Boichot E., Germain N., Allain N., Anger J.P., Lagente V. Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol. 330:1997;231-240.
43. Stefano G.B., Salzet M., Bilfinger T.V. Long-term exposure of human blood vessels to HIV gp120, morphine, and anandamide increases endothelial adhesion of monocytes uncoupling of nitric oxide release . J Cardiovasc Pharmacol. 31:1998;862-868.
44. Stefano G.B., Liu Y., Goligorsky M.S. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. J Biol Chem. 271:1996;19238-19242.
45. Jeon Y.J., Yang K.H., Pulaski J.T., Kaminski N.E. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. Mol Pharmacol. 50:1996;334-341.
46. Richardson J.D., Aanonsen L., Hargreaves K.M. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol. 345:1998;145-153.
47. 1 receptor expression in rat spinal cord. Mol Cell Neurosci 2000; in press.
48. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., Julius D., Hogestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:1999;452-457.
49. Schmid H.H.O., Schmid P.C., Natarajan V. N-Acylated glycerophospholipids and their derivatives. Prog Lipid Res. 29:1990;1-43.
50. Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol. 300:1996;227-236.
51. Martin W.J., Loo C.M., Basbaum A.I. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain. 82:1999;199-205.
52. Smith F.L., Fujimori K., Lowe J., Welch S.P. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav. 60:1998;183-191.
53. 2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 76:1998;189-199.
54. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
55. 2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. Neurosci Lett. 253:1998;123-126.
56. Stengel P.W., Rippy M.K., Cockerham S.L., Devane W.A., Silbaugh S.A. Pulmonary actions of anandamide, an endogenous cannabinoid receptor agonist, in guinea pigs. Eur J Pharmacol. 355:1998;57-66.
57. Berdyshev E., Boichot E., Corbel M., Germain N., Lagente V. Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci. 63:1998;L125-L9.
58. Kondo S., Sugiura T., Kodaka T., Kudo N., Waku K., Tokumura A. Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis. Arch Biochem Biophys. 354:1998;303-310.
59. Beaulieu P, Bisogno T, Punwar S, Farquhar-Smith WP, Ambrosino G, Di Marzo V, Rice ASC. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol; in press.
60. Munson A.E., Harris L.S., Friedman M.A., Dewey W.L., Carchman R.A. Antineoplastic activity of cannabinoids. J Natl Cancer Inst. 55:1975;597-602.
61. Carchman R.A., Harris L.S., Munson A.E. The inhibition of DNA synthesis by cannabinoids. Cancer Res. 36:1976;95-100.
62. White A.C., Munson J.A., Munson A.E., Carchman R.A. Effects of delta9-tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. J Natl Cancer Inst. 56:1976;655-658.
63. Friedman M.A. In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis lung carcinomas. Cancer Biochem Biophys. 2:1977;51-54.
64. Tucker A.N., Friedman M.A. Effects of cannabinoids on L1210 murine leukemia. 1. Inhibition of DNA synthesis. Res Commun Chem Pathol Pharmacol. 17:1977;703-714.
65. Dvilansky A, Zolotov Z, Herzliker B, Nathan I. Effects of ethanol, CBD and δ-9 THC on proliferation of K-562 cells. Int J Tissue React 1984;6:409-12.
66. Murison G., Chubb C.B., Maeda S., Gemmell M.A., Huberman E. Cannabinoids induce incomplete maturation of cultured human leukemia cells. Proc Natl Acad Sci USA. 84:1987;5414-5418.
67. Baek S.H., Kim Y.O., Kwag J.S., Choi K.E., Jung W.Y., Han D.S. Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Arch Pharm Res. 21:1998;353-356.
68. Sanchez C., Galve-Roperh I., Canova C., Brachet P., Guzman M. Δ9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 436:1998;6-10.
69. Ruiz L., Miguel A., Díaz-Laviada I. Δ9-Tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett. 458:1999;400-404.
70. Tahir S.K., Trogadis J.E., Stevens J.K., Zimmerman A.M. Cytoskeletal organization following cannabinoid treatment in undifferentiated and differentiated PC12 cells. Biochem Cell Biol. 70:1992;1159-1173.
71. Wilson R.G. Jr, Tahir S.K., Mechoulam R., Zimmerman S., Zimmerman A.M. Cannabinoid enantiomer action on the cytoarchitecture. Cell Biol Int. 20:1996;147-157.
72. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol. 46:1993;791-796.
73. Bisogno T., Sepe N., Melck D., Maurelli S., De Petrocellis L., Di Marzo V. Biosynthesis, release, and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoyl-glycerol in mouse neuroblastoma cells. Biochem J. 322:1997;671-677.
74. Basavarajappa B.S., Hungund B.L. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells. J Neurochem. 72:1999;522-528.
75. Bisogno T., Katayama K., Melck D., Ueda N., De Petrocellis L., Yamamoto S., Di Marzo V. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells-implications for cell proliferation and differentiation. Eur J Biochem. 254:1998;634-642.
76. Chilton F.H., Surette M.E., Winkler J.D. Arachidonate-phospholipid remodeling and cell proliferation. Adv Exp Med Biol. 416:1996;169-172.
77. De Petrocellis L., Melck D., Palmisano A., Bisogno T., Laezza C., Bifulco M., Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA. 95:1998;8375-8380.
78. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V. Suppression of trk and prolactin receptor levels by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000;141:118-26.
79. Morre D.J., Chueh P.J., Morre D.M. Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Proc Natl Acad Sci USA. 92:1995;1831-1835.
80. 1 cannabinoid receptors . Biochem Biophys Res Commun. 262:1999;275-284.
81. Cravatt B.F., Prospero-Garcia O., Siuzdak G., Gilula N.B., Henriksen S.J., Boger D.L. Chemical characterization of a family of brain lipids that induce sleep. Science. 268:1995;1506-1509.
82. Maurelli S., Bisogno T., De Petrocellis L., Di Luccia A., Marino G., Di Marzo V. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. FEBS Lett. 377:1995;82-86.
83. Mechoulam R, Fride E, Hanu L, Sheskin T, Bisogno T, Di Marzo V, Bayewitch M, Vogel Z. Anandamide may mediate sleep induction. Nature 1997;389:25-6.
84. Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M.H., Vogel Z., Bisogno T., De Petrocellis L., Di Marzo V., Mechoulam R. An entourage effect inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity . Eur J Pharmacol. 353:1998;23-31.
85. Ruh M.F., Taylor J.A., Howlett A.C., Welshons W.V. Failure of cannabinoid compounds to stimulate estrogen receptors. Biochem Pharmacol. 53:1997;35-41.
86. Descamps S., Lebourhis X., Delehedde M., Boilly B., Hondermarck H. Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells. J Biol Chem. 273:1998;16659-16662.
87. Geldof A.A., van Haarst E.P., Newling D.W.W. Neurotrophic factors in prostate and prostatic cancer. Prostate Cancer and Prostatic Diseases. 5:1998;236-241.
88. Pflug B., Djakiew D. Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor-induced cell growth by activation of programmed cell death. Mol Carcinog. 23:1998;106-114.
89. Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M, Di Marzo V. Inhibition of the cAMP/protein kinase A pathway and stimulation of mitogen-activated protein kinase underlie the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 1999;463:235-40.
90. Guzman M., Sanchez C. Effects of cannabinoids on energy metabolism. Life Sci. 65:1999;657-664.
91. Ehrhard P.B., Ganter U., Stalder A., Bauer J., Otten U. Expression of functional trk protooncogene in human monocytes. Proc Natl Acad Sci USA. 90:1993;5423-5427.
92. Di Marzo V., Deutsch D.G. Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis. 5:1998;386-404.
93. Di Marzo V., Sepe N., De Petrocellis L., Berger A., Crozier G., Fride E. Mechoulam R, Trick or treat from food endocannabinoids. Nature. 396:1998;636.
94. Klein TW, Newton C, Nakachi N, Friedman H. Suppression of T helper 1 (Th1) immunity by THC, In: Symposium on the Cannabinoids, International Cannabinoid Research Society 1999;1999:43.
95. Tashkin DP, Zhu L, Sharma S, Stolina M, Gardner B, Roth MD, et al. Delta9-tetrahydrocannabinol mediates cytokine-dependent inhibition of anti-tumor immune reactivity in vivo. In: 1999 Symposium on the Cannabinoids, International Cannabinoid Research Society 1999;41.
96. Lichtman A, Gifford G, Damaj I, Martin BR. Evaluation of the cannabinoid antagonist SR141716A in acute and chronic models of nociception in mice, submitted.
97. 2, a peripheral cannabinoid receptor . Proc Natl Acad Sci USA. 96:1999;14228-14233.
98. 2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60. FEBS Lett. 448:1999;273-277.
99. Kuwae T., Shiota Y., Schmid P.C., Krebsbach R., Schmid H.H. Biosynthesis and turnover of anandamide and other N-acylethanolamines in peritoneal macrophages. FEBS Lett. 459:1999;123-127.